Evaluation of Increase in the Adhesion Molecules (Icam-1, Vcam-1) according to the Types of Atrial FibrillationKilci H*, Koksal C, Lutfu B, Ilksen AG and Orhan O
Sisli Etfal Education and Research Hospital, Istanbul, Turkey
- *Corresponding Author:
- Kilci H
Sisli Etfal Education and Research Hospital
E-mail: [email protected]
Received Date: November 11, 2015; Accepted Date: November 26, 2015; Published Date: December 12, 2015
Citation: Kilci H, Koksal C, Lutfu B, Ilksen AG, Orhan O (2015) Evaluation of Increase in the Adhesion Molecules (Icam-1, Vcam-1) according to the Types of Atrial Fibrillation. J Vasc Med Surg 3:234. doi:10.4172/2329-6925.1000234
Copyright: © 2015 Kilci H, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Aim: we aimed to evaluate the levels of vascular cell adhesion molecule-1 (vcam-1) and intercellular adhesion molecule-1 (icam-1) at the patients with valvular and nonvalvular atrial fibrillation.
Methods: 45 control patient with normal sinus rhythm and 44 patients with valvular atrial fibrillation (vaf) or nonvalvular atrial fibrillation (nvaf), total 89 subjects whose Coronary arteries were found to be normal with angiography were included in the study.
Results: There was not any significant difference between the control and atrial Fibrillation (af) group in term of plasma icam-1 levels (706 ± 180 mg/dl vs. 671 ± 132 Mg/dl, p = 0.313). Plasma vcam-1 levels were found to be higher in the af group than The control group (1169 ± 246 mg/dl vs. 1072 ± 229 mg /dl, p = 0.056). In the atrial Fibrillation group there were 17 vaf and 27 nvaf patients. In the subgroup analysis According to the type of atrial fibrillation; there were statistically significant differences between the control and vaf and nvaf groups in terms of vcam-1 levels (1260 ± 291 vs. 1113 ± 198 vs. 1072 ± 229, p = 0.021). It is shown that the detected differences in Term of vcam-1 between the atrial fibrillation group and control group are particularly Due to the differences between the vaf and control groups (vaf and control groups; 1260 ± 291 mg/dl vs. 1072 ± 229 mg/dl, p=0.016, respectively). For icam-1 levels any differences between vaf and nvaf groups were not detected (748 ± 203 vs. 680 ± 163 vs. 671 ± 132, p = 0.216).
Conclusion: in this study, vcam-1 levels were found to be higher at the patients with vaf. We think that increased vcam-1 levels at the patients with vaf can be related with the increased risk of thromboembolic events.